Agreement with Canntab Therapeutics TORONTO, Dec. 2, 2021 /CNW/ - Pathway Health Corp. (TSXV: PHC) (formerly Colson Capital Corp.) ("Pathway" or the "Company") is pleased to announce that it has entered into a Service Agreement (the "Agreement") with Canntab Therapeutics Limited ("PILL"), a Canadian biopharmaceutical company focused on the manufacturing and distribution of a full suite of oral tablet cannabinoid products.
"We are pleased with the opportunity to provide Canntab's oral tablet cannabinoid products to our patients and the patients of our pharmacy partners" said Ken Yoon, CEO of Pathway Health. "These products will consist of a range of dosages of both THC and CBD medications and will made available to our patients under the existing Cannabis Act legislation."